Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple ...

Discover Halozyme's groundbreaking patent for modified PH20 hyaluronidase polypeptides, showcasing enhanced stability and activity for innovative therapeutic applications.

Deservedly or not, filler has a PR problem. Public enthusiasm for the injections has cooled in recent years, as we’ve watched ...

The US Food and Drug Administration (FDA) has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc ...

Astute Analytica has released a comprehensive report on the Global Hyaluronidase Market, providing an in-depth analysis of its current and future landscape. This market research document identifies ...

The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received U.S. Food and Drug Administration ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...

The FDA has approved Roche's Ocrevus Zunovo for relapsing and primary progressive multiple sclerosis, offering the first ...

The Food and Drug Administration (FDA) has approved Tecentriq Hybreza ™ (atezolizumab and hyaluronidase-tqjs) for subcutaneous (SC) injection, for all the approved adult indications of intravenous ...

ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) ...

Ocrevus Zunovo is a combination of ocrelizumab, a CD20-directed cytolytic antibody, and hyaluronidase-ocsq, an endoglycosidase. The Food and Drug Administration (FDA) has approved Ocrevus Zunovo™ ...